On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window. I would put this at better than even and not much better.
Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset
Two things I would like separated before anyone answers on published dose-response for semaglutide, because they get bundled and then argued about as one thing.
The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.
Published dose-response for semaglutide has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
This follows post #2 rather than contradicting it.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
I have said this before in a thread nobody could find, so it is worth repeating.
Grateful for the specificity. Vague answers to this question are what sent me looking.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
I would put this at better than even and not much better.
An observation about published dose-response for semaglutide that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Taking post #6 at face value and following it one step further.
On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.
The reason published dose-response for semaglutide is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Everything in post #8 holds. The case it does not cover is the one I have.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Summarising the published dose-response for semaglutide thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Post #11 is the version of this I will quote in future. One addition.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
I would put a moderate confidence on that and no more.
Answering the question post #11 raises rather than the one it answers.
I would call the community position on published dose-response for semaglutide likely rather than established, and I would be comfortable defending that hedge.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
Counterpoint on published dose-response for semaglutide, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
That is what the documentation says. What happens in practice is usually close.
Post #15 describes the usual case. This is about the unusual one.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
I checked the source rather than the summary, and they differ.
Adding the measurement that post #15 says would settle it.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the second asks what happens when it is withdrawn after a run-in. Quoting the first as evidence about maintenance is the commonest misreading of the programme.
The version of published dose-response for semaglutide that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
On post #18 — agreed on the reasoning, with one qualification.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
I disagree with the framing of published dose-response for semaglutide above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
I would rather say I do not know than round it up to an answer.
Adding the measurement that post #24 says would settle it.
A request rather than an answer: could whoever has the primary source for published dose-response for semaglutide post it? I have seen the claim three times this month and each version had lost a qualifier.
Post #22 describes the usual case. This is about the unusual one.
Source for the published dose-response for semaglutide figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
Seconded. It reads as careful rather than confident, which is the right register.
I changed my mind about published dose-response for semaglutide after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
I am confident about the direction and much less about the magnitude.